ClinConnect ClinConnect Logo
Search / Trial NCT06257420

Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions

Launched by SIMMARON RESEARCH INC. · Feb 12, 2024

Trial Information

Current as of July 23, 2025

Enrolling by invitation

Keywords

Me/Cfs Long Covid Infection Associated Chronic Conditions

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Diagnosis of ME/CFS that meets the Institute of Medicine (IOM) criteria
  • Diagnosis of Long-COVID (PASC clinical criteria)
  • Exclusion Criteria:
  • No diagnosis of ME/CFS or Long-COVID

About Simmaron Research Inc.

Simmaron Research Inc. is a pioneering clinical research organization dedicated to advancing medical science through the management and execution of clinical trials. With a focus on innovative therapies and patient-centered approaches, Simmaron collaborates with pharmaceutical and biotechnology companies to facilitate the development of new treatments across various therapeutic areas. Their experienced team employs rigorous methodologies and adheres to the highest ethical standards to ensure the integrity and reliability of clinical data. By fostering partnerships and leveraging cutting-edge technology, Simmaron Research Inc. aims to accelerate the journey from research to market, ultimately enhancing patient outcomes and contributing to the advancement of healthcare.

Locations

Rochester, Minnesota, United States

Incline Village, Nevada, United States

Salt Lake City, Utah, United States

Palo Alto, California, United States

Seattle, Washington, United States

Patients applied

0 patients applied

Trial Officials

Gunnar Gottschalk, PhD

Principal Investigator

Simmaron Research Inc.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported